Document is current
Any future updates will be listed below
-
Authors
Latif, Muhammad A.
Tunacao, Jessa M.
Fu, Yingli
Moran, Timothy H.
Yenokyan, Gayane
Fischman, Aaron M.
Cheskin, Lawrence J.
Holly, Brian P.
Hong, Kelvin
Shin, Eun J.
Steele, Kimberley E.
Kraitchman, Dara L.
Arepally, Aravind
Weiss, Clifford R. https://orcid.org/0000-0003-2180-1731
-
Funding
Funding for this research was provided by:
Merit Medical
Siemens USA
- License Information
-
More Information
Article History
Received: 16 March 2022
Accepted: 2 September 2022
First Online: 22 September 2022
Declarations
:
: The following authors report no conflicts of interest: MAL, JT, YF, THM, GY, AMF, LJC, BPH, EJS, KES, and AA. KH reports the following (unrelated to this study): consultancy/grant support from Boston Scientific, consultant advisory board for AstraZeneca. DLK reports the following (unrelated to the study): scientific advisor board for Ardent Animal Health. CRW reports the following: (related to this study) consultancy/grant support from Medtronic, Boston Scientific; (unrelated to this study) consultant/grant support from Siemens Healthcare, medical advisory board of ClearGuide Medical and PneumoNix Medical, and co-founder of Shuriken Medical and Avasys.
: This prospective study was approved by both hospitals’ institutional review boards and complies with the Declaration of Helsinki, (ClinicalTrials.gov identifier: NCT02165124). Patients with obesity were recruited for BAE through the Bariatric Embolization of Arteries for the Treatment of Obesity (BEAT Obesity) Trial, a prospective, open-label, single-arm, 2-center study, from June 2, 2014, to February 16, 2018.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
